Ghent University Academic Bibliography

Show Sort by

Your filters: cql: parent exact "BLOOD"

Add to list
- Conference Paper
- C3
CD8 presence and dynamics in glofitamab-treated patients with relapsed/refractory B-cell Non-Hodgkin lymphoma using the CD8-specific PET tracer Zr-89-crefmirlimab berdoxam

Martin Hutchings, Annika Loft, Wendy Osborne, George Petrides, Fritz Offner (UGent) , Ciel De Vriendt (UGent) , Giuseppe Gritti, Roberto Boni, William Townsend, Irfan Kayani, et al.

(2022) BLOOD. In Blood 140(Supplement 1). p.10733-10735
Add to list
- Conference Paper
- C3
Ciltacabtagene autoleucel (cilta-cel), a BCMA-directed CAR-T cell therapy, in patients with multiple myeloma (MM) and early relapse after initial therapy : CARTITUDE-2 cohort B 18-month follow-up

Niels W. C. J. Van de Donk, Mounzer Agha, Adam D. Cohen, Yael C. Cohen, Sebastien Anguille, Tessa Kerre (UGent) , Wilfried W. H. Roeloffzen, Jordan M. Schecter, Kevin C. De Braganca, Carolyn C. Jackson, et al.

(2022) BLOOD. In Blood 140(Supplement 1). p.7536-7537
Add to list
- Conference Paper
- C3
RG6234, a GPRC5DxCD3 T-cell engaging bispecific antibody, is highly active in patients (pts) with relapsed/refractory multiple myeloma (RRMM) : updated intravenous (IV) and first subcutaneous (SC) results from a phase I dose-escalation study

Carmelo Carlo-Stella, Rita Mazza, Salomon Manier, Thierry Facon, Sung-Soo Yoon, Youngil Koh, Simon J. Harrison, Jeremy Er, Antonio Pinto, Francesco Volzone, et al.

(2022) BLOOD. In Blood 140(Supplement 1). p.397-399
Add to list
- Conference Paper
- C3
Long-term clinical outcomes and correlative efficacy analyses in patients (pts) with relapsed/refractory follicular lymphoma (r/r FL) treated with tisagenlecleucel in the ELARA trial

Martin Dreyling, Michael Dickinson, Joaquin Martinez Lopez, Arne Kolstad, Jason P. Butler, Monalisa Ghosh, Leslie L. Popplewell, Julio Chavez, Emmanuel Bachy, Koji Kato, et al.

(2022) BLOOD. In Blood 140(Supplement 1). p.1459-1463
Add to list
- Conference Paper
- C3
Intravenous and subcutaneous administration of RG6234, a novel GPRC5DxCD3 T-cell engaging bispecific antibody, is highly active in patients with relapsed/refractory multiple myeloma (RRMM) : biomarker results from a phase I study

Iryna Dekhtiarenko, Iva Lelios, Jan Attig, Nassim Sleiman, Domenico Lazzaro, Emilie Schindler, Jan Eckmann, Pablo Umana, Wolfgang Jacob, Meike Schneider, et al.

(2022) BLOOD. In Blood 140(Supplement 1). p.10137-10139
Add to list
- Conference Paper
- C3
CD19 4-1BBL (RO7227166) a novel costimulatory bispecific antibody can be safely combined with the T-Cell engaging bispecific antibody glofitamab in relapsed or refractory B-cell Non-Hodgkin lymphoma

Martin Hutchings, Carmelo Carlo-Stella, Giuseppe Gritti, Francesc Bosch, Franck Morschhauser, William Townsend, Fritz Offner (UGent) , Harriet S. Walter, Herve Ghesquieres, Roch Houot, et al.

(2022) BLOOD. In Blood 140(Supplement 1). p.9461-9463
Add to list
- Conference Paper
- C3
Five-year results and overall survival update from the phase 3 randomized study AUGMENT : lenalidomide plus rituximab (R-2) vs rituximab plus placebo in patients with relapsed/refractory indolent Non-Hodgkin lymphoma

John P. Leonard, Marek Trneny, Fritz Offner (UGent) , Jiri Mayer, Huilai Zhang, Grzegorz S. Nowakowski, Phillip Scheinberg, Argyrios Gkasiamis, Joanna Mikita-Geoffroy, Everton Rowe, et al.

(2022) BLOOD. In Blood 140(Supplement 1). p.561-563
Add to list
- Conference Paper
- C3
Subcutaneous epcoritamab in combination with rituximab plus lenalidomide (R-2) for first-line treatment of follicular lymphoma : initial results from phase 1/2 trial

Lorenzo Falchi, Lori A. Leslie, David Belada, Katerina Kopeckova, Fritz Offner (UGent) , Joshua Brody, Miguel Canales, Alejandro Martin Garcia-Sancho, Marcel Nijland, P-O Andersson, et al.

(2022) BLOOD. In Blood 140(Supplement 1). p.1471-1473
Add to list
- Conference Paper
- C3
Glofitamab monotherapy induces high complete response rates in patients with heavily pretreated relapsed or refractory mantle cell lymphoma

Tycel J. Phillips, Michael Dickinson, Franck Morschhauser, Emmanuel Bachy, Michael Crump, Marek Trneny, Nancy L. Bartlett, Jan Zaucha, Tomasz Wrobel, Fritz Offner (UGent) , et al.

(2022) BLOOD. In Blood 140(Supplement 1). p.178-180
Add to list
- Journal Article
- A1
Breakthrough COVID-19 in vaccinated patients with hematologic malignancies : results from EPICOVIDEHA survey

Livio Pagano, Jon Salmanton-García, Francesco Marchesi, Ola Blennow, Maria Gomes da Silva, Andreas Glenthøj, Jaap A. van Doesum, Yavuz M Bilgin, Alberto Lopez-Garcia, Federico Itri, et al.

(2022) BLOOD. 140(26). p.2773-2787

Academic Bibliography

CD8 presence and dynamics in glofitamab-treated patients with relapsed/refractory B-cell Non-Hodgkin lymphoma using the CD8-specific PET tracer Zr-89-crefmirlimab berdoxam

Ciltacabtagene autoleucel (cilta-cel), a BCMA-directed CAR-T cell therapy, in patients with multiple myeloma (MM) and early relapse after initial therapy : CARTITUDE-2 cohort B 18-month follow-up

RG6234, a GPRC5DxCD3 T-cell engaging bispecific antibody, is highly active in patients (pts) with relapsed/refractory multiple myeloma (RRMM) : updated intravenous (IV) and first subcutaneous (SC) results from a phase I dose-escalation study

Long-term clinical outcomes and correlative efficacy analyses in patients (pts) with relapsed/refractory follicular lymphoma (r/r FL) treated with tisagenlecleucel in the ELARA trial

Intravenous and subcutaneous administration of RG6234, a novel GPRC5DxCD3 T-cell engaging bispecific antibody, is highly active in patients with relapsed/refractory multiple myeloma (RRMM) : biomarker results from a phase I study

CD19 4-1BBL (RO7227166) a novel costimulatory bispecific antibody can be safely combined with the T-Cell engaging bispecific antibody glofitamab in relapsed or refractory B-cell Non-Hodgkin lymphoma

Five-year results and overall survival update from the phase 3 randomized study AUGMENT : lenalidomide plus rituximab (R-2) vs rituximab plus placebo in patients with relapsed/refractory indolent Non-Hodgkin lymphoma

Subcutaneous epcoritamab in combination with rituximab plus lenalidomide (R-2) for first-line treatment of follicular lymphoma : initial results from phase 1/2 trial

Glofitamab monotherapy induces high complete response rates in patients with heavily pretreated relapsed or refractory mantle cell lymphoma

Breakthrough COVID-19 in vaccinated patients with hematologic malignancies : results from EPICOVIDEHA survey

Contents

Support

Contact